Why Is Insulet Stock Up More Than 15% Over The Last Month?

Forbes Finance 2 weeks ago

Insulet (NASDAQ: PODD), a company best known for selling the Omnipod continuous insulin delivery system that caters to people with diabetes, has seen its stock price rally by close to 17% over the last month. There have been multiple factors driving the rally. Firstly, the company posted stronger than expected Q3 results earlier this month, with revenues growing by ~27% year-over-year to $192 million, beating estimates by almost $13 million, driven by strong sales of the Omnipod system. The company has had some favorable news on the regulatory front, gaining FDA approval for the use of Novo Nordisk’s Fiasp -a fast-acting mealtime insulin – with the Omnipod insulin management platform. Separately, in September, the FDA cleared the company’s ACE pump. This could help the company drive revenue growth.

We ‘step back’ from these recent swings to review Insulet’s performance over the last few years, as a context for what might come next. Our Interactive dashboard, Why Has Insulet Stock Rallied Over The Last Month?, reviews the near term reasons and the big picture.

The context for the last few years:

A closer look At Insulet’s Total Revenues over the last few years and the outlook

Revenues

Total Revenues for Insulet significantly increased from $464 Mil in 2017 to $564 Mil in 2018; an increase of 21.6%.

This compares with Total Revenues growth of:

  • 14.1% in 2015
  • 39.1% in 2016
  • 26.4% in 2017

We expect Total Revenues growth to be 29.5% in 2019.

A closer look At Insulet’s Total Expenses over the last few years and the outlook

Total Expense for Insulet increased from $490 Mil in 2017 to $559 Mil in 2018; an increase of 13.9%.

This compares with Total Expense growth of:

  • 16.5% in 2015
  • 21.1% in 2016
  • 24.5% in 2017

We expect Total Expense growth to stand at 28% in 2019.

How does Insulet’s Revenue Growth compare with Abbott and Tandem Diabetes Care?

For more information on how Insulet’s revenue growth compares with rivals, view our interactive dashboard analysis.

How has Insulet’s EBT trended?

EBT for Insulet increased dramatically by -120% from -$26.6 Mil in 2017 to $5.23 Mil in 2018.

We expect EBT to increase to $16.6 million in 2019.

How has Insulet’s Net Income and EPS trended?

For more information on Insulet’s Net Income and EPS, view our interactive dashboard analysis.

What’s behind Trefis? See How It’s Powering New Collaboration and What-Ifs For CFOs and Finance TeamsProduct, R&D, and Marketing Teams More Trefis Data Like our charts? Explore example interactive dashboards and create your own

Tags: Money

Source link
Read also:
Forbes › Finance › 5 days ago
Datadog (NASDAQ: DDOG), a software as a service company that provides monitoring and analytics for cloud applications, has seen its stock price rise by about 20% over the last month to about $41 per share. The stock is up 51% from its IPO price of $27...
Forbes › Finance › 5 days ago
Dynatrace (NYSE: DT) is a company that provides a software intelligence platform designed for the enterprise cloud. While the stock saw some volatility post its early-August IPO, it has rallied by close to 28% over the last month, trading at levels of...
Forbes › Finance › 2 weeks ago
LiveRamp Holdings (NYSE: RAMP), a software as a service (SaaS) company that helps to match customer data sets for brands and marketers, has seen its stock price rise by more than 20% over the last month. The rally is likely driven by the company’s Q2...
Forbes › Finance › 1 week ago
CarGurus (NASDAQ: CARG), an online automobile market place that connects buyers and sellers of new and used cars, has seen its stock price rise by about 30% over the last month. The rally is driven partly by the company’s stronger than expected Q3...
Forbes › Finance › 1 week ago
Ceridian HCM Holding (NYSE: CDAY), a company that develops human capital management software, has seen its stock price rise by about 35% over the last month. The rally was likely driven partly by stronger than expected Q3 results, with adjusted...
Forbes › Finance › 2 weeks ago
Arrowhead Pharmaceuticals (NASDAQ: ARWR), a company that focuses on the treatment of intractable diseases by targeting the genes that cause them, has seen its stock rise by over 30% over the last month. The company currently has a pipeline of 9 drugs...
Forbes › Finance › 1 month ago
Alteryx (NYSE: AYX) is a data science and analytics software company, specializing in self-service analytics. While the stock has rallied by over 60% year-to-date, it saw a significant selloff over the last week, with its stock price falling by roughly...
Forbes › Finance › 1 month ago
Noble Energy (NYSE: NBL) is an independent energy company engaged in the production of Oil and Gas. The company’s stock has declined by about 20% over the last month, and this could be due to two broad reasons. Firstly, in September, Saudi Arabian...
Forbes › Finance › 1 week ago
Entertainment company AMC Networks (NASDAQ: AMCX) has seen its stock price decline by almost 20% over the last month. The decline is likely driven by a mixed Q3 2019 earnings report by the company, with revenues coming in below street estimates...
Forbes › Finance › 1 week ago
Centurylink (NYSE: CTL), a company that provides communications, network services, security, cloud solutions, and voice as well as managed services, has seen its stock price rise by about 18% over the last month. The rally is likely driven by the...
Sign In

Sign in to follow sources and tags you love, and get personalized stories.

Continue with Google
OR